SynthesisBMC pediatrics2025
Clinical features, treatment and prognosis of primary pulmonary rhabdomyosarcoma: A systemic review.
Synthesis in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Development and validation of an MRI radiomics-based model for predicting progression risk in prostate cancer after endocrine therapy.Translational andrology and urology · 2026Article
- Primary peritoneal embryonal rhabdomyosarcoma in a 6-year-old girl with rapid post-surgical peritoneal recurrence possibly due to surgical tumor seeding: a case report and review of the literature.Journal of medical case reports · 2026Review
- Differential diagnosis of testicular embryonal rhabdomyosarcoma and testicular seminoma with enhanced CT: a retrospective study.Frontiers in oncology · 2026Article
- A rare incidence of primary pulmonary undifferentiated pleomorphic sarcoma detected as an endobronchial mass and treated by bronchoscopic resection: a case report and literature review.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPrimary pulmonary rhabdomyosarcoma (RMS), a rare soft tissue sarcoma, is characterized by a high recurrence rate and a poor prognosis. This systematic review aims to summarize the clinical characteristics, pathological features, treatment, and clinical outcomes of primary pulmonary RMS, and to analyze prognostic-related risk factors to provide robust evidence for future treatment strategies.
methodsFive databases (MEDLINE, Scopus, the Cochrane Central Register of Controlled Trials, EMBASE, and Web of Science) were searched using the relevant terms including "pulmonary", "lung", "alveolar", "ERMS", "ARMS", "RMS" and "rhabdomyosarcoma". Cases with a definitive pathological diagnosis of RMS, complete treatment information, a minimum follow-up period of at least three months, and detailed follow-up records were included. The primary study endpoints were cancer-specific survival (CSS) and progression-free survival (PFS).
results22 articles spanning from 1955 to 2023 met the inclusion criteria for the systematic review. The median patient age was 10.5 (2.0, 52.5) years. 22 cases (78.6%) presented with respiratory symptoms due to pulmonary masses at the initial diagnosis. 10 cases were diagnosed with the embryonal type, and the majority (n = 20, 71.4%) underwent surgical treatment. The average PFS time was 60.9 ± 14.8 months. Patients at TNM stage IV were more prone to progression, and CSS was associated with factors including age ≥ 18 years, primary tumor size ≥ 10 cm, and non-surgical treatment. Surgery was identified as an independent factor that could shorten progression time (HR = 4.58 (1.32-15.90), P = 0.017) and improve tumor-related survival (HR = 8.11 (1.45-45.50), P = 0.017).
conclusionsPatients with higher TNM stages who did not undergo surgery tended to have more aggressive tumors, whereas primary tumors ≥ 10 cm and ages ≥ 18 years were associated with increased tumor-related mortality. Surgery, the primary treatment modality, independently improved CSS rates. Exploring optimal comprehensive treatment strategies that combine surgery, radiotherapy, and chemotherapy represents the principal direction for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.